Achiko AG

Regulatory Filings • Aug 28, 2020

News Details

Ad-hoc | 28 August 2020 05:28

Achiko AG: Achiko Disposes of EmpatKali Holdings and Focuses on Covid-19 Testing Technology

Achiko AG / Key word(s): Disposal

28-Aug-2020 / 05:28 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 KR

The issuer is solely responsible for the content of this announcement.

---

Achiko Disposes of EmpatKali Holdings and Focuses on Covid-19 Testing Technology

Zurich, 28 August 2020 – Achiko AG (SWX:ACHI, ISIN CH0522213468) is selling its stake in the company EmpatKali. The buyer of EmpatKali is Afterpay, a public listed company. EmpatKali offers a “buy now, pay later” business.

Achiko will receive the initial investment of USD 100,000. The proceeds of the sale of Achiko’s holdings will be applied to the development of Gumnuts, Achiko’s Covid-19 testing solution in Asia and Europe.

About Achiko AG

Headquartered in Switzerland, with a global market focus, Achiko AG (ISIN CH0522213468) is an entrepreneurial platform company, utilising the knowledge and experience of its people and key technologies to enable transformation in various industries.

Through innovations in technology and regulation along with the company’s unique operating footprint from Europe to Asia, Achiko seeks to transform markets and bring unique value to its customers, people, and shareholders. Achiko’s core platform consists of user registration and payment services which are accessible to application developers. A messaging service and other community based social features are being launched in late 2020. Achiko supports innovations in healthcare through its Teman Sehat (“Health Buddy”) ecosystem, its Gumnuts novel saliva Covid-19 testing technology based on DNA aptamers developed with Regenacellx.sl, as well as consumer payments and finance and games and entertainment.

For any inquiries regarding Gumnuts or Teman Sehat, please contact info@achiko.com

Further information about Achiko can be found at https://www.achiko.com

Further information about the Teman Sehat ecosystem can be found at https://www.temansehat.co

Further information about Regenacellx.sl can be found at https://regenacellx.com

Further information about Empatkali can be found at https://empatkali.co.id

Investor Relations & Press Contact:

ACHIKO AG

Investor Relations

E: ir@achiko.com

Switzerland

Marcus Balogh

Farner Consulting Ltd.

E: achiko@farner.ch

T: +41 44 266 67 67

Germany and Austria

Axel Mühlhaus / Dr Sönke Knop

edicto GmbH

E: achiko@edicto.de

T: +49 69 90 55 05-51

*Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

---

End of ad hoc announcement

---

Language:	English
Company:	Achiko AG
	Lavaterstrasse 66
	8002 Zurich
	Switzerland
Internet:	https://investor.achiko.com/
ISIN:	CH0522213468
Valor:	48788430
Listed:	SIX Swiss Exchange
EQS News ID:	1124485

End of Announcement	EQS Group News Service